Navigation Links
DNA Test May Cut Hospitalizations Caused by Blood Thinner
Date:3/16/2010

Determining sensitivity can prevent bleeding, clotting problems, study shows

TUESDAY, March 16 (HealthDay News) -- A simple genetic test that helps doctors determine the best dose of the blood-thinner drug warfarin for individual patients could reduce hospitalizations by one-third during the early dose-adjustment phase, a new study has found.

The test identifies variations in two genes that strongly influence sensitivity to warfarin (Coumadin), which is used to prevent blood clots in people with high-risk conditions, such as atrial fibrillation, or after surgery to replace a heart valve.

"Genetic testing is a tool clinicians can use to more accurately predict the best warfarin dose early on," Dr. Robert S. Epstein, chief medical officer and president of the Medco Research Institute in Franklin Lakes, N.J., said in a news release from the American College of Cardiology. "Patients may get to a stable dose more quickly and, therefore, have a lower risk of negative outcomes, such as excess bleeding or unwanted blood clotting."

The findings were to be presented Tuesday at the college's annual meeting in Atlanta.

The study included 896 people who, shortly after beginning warfarin therapy, gave a blood sample or cheek swab that was analyzed for expression of two genes -- CYP2C9 and VKORC1 -- that revealed sensitivity to warfarin. People with high sensitivity were put on a reduced dose of warfarin and had frequent blood tests. People with low sensitivity were given a higher dose of warfarin.

During the first six months that they took warfarin, those who underwent genetic testing were 31 percent less likely to be hospitalized for any reason and 29 percent less likely to be hospitalized for bleeding or thromboembolism than were a group that did not have genetic testing.

Epstein said that the cost of the genetic testing -- $250 to $400 -- would be justified by reduced hospitalization costs.

"If we reduce just two hospitalizations per 100 patients tested, that more than compensates for the cost of genotyping," he said.

More information

The U.S. Agency for Healthcare Research and Quality explains the safe use of blood thinners.



-- Robert Preidt



SOURCE: American College of Cardiology, news release, March 16, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007
2. Air pollution linked to hospitalizations for pneumonia in seniors
3. Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care
4. Swine Flu May Bring Surge in Hospitalizations
5. Fertility Treatment Twins More at Risk for Hospitalizations
6. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
7. Avalere Shows Home Health Interventions Associated with Lower Medicare Spending and Re-Hospitalizations for Patients With Chronic Illness
8. American Heart Association Leads Efforts to Reduce Preventable Deaths and Rehospitalizations for Heart Failure Patients
9. High Rate of Rehospitalizations Costing Billions
10. Global warning: Hotter days, increased hospitalizations for respiratory problems
11. Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , ... Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day ... at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: